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Objectives. This study sought to determine the prevalence of 
autoantibodies directed against the beta-adrenoceptors in pa- 
tients with primary electrical cardiac abnormalities, including 
atrial arrhythmias, ventricular arrhythmias and conduction dis- 
turbances, in the absence of any other cardiac abnormality. 
Background. Using synthetic peptides corresponding to the 
predicted sequences for the second extracellular loop f the 
human betat, and beta2-adrenoceptors as antigenic targets, au- 
toantibodies directed against the beta-adrenoceptors were re- 
cently shown to occur in patients with idiopathic dilated cardio- 
myopathy and Chagas' heart disease. 
Methods. Eighty-six patients (57 with primary electrical abnor- 
malities, 29 with idiopathic dilated cardiomyopathy) and 101 
healthy and cardiopathic control subjects were studied. Antibod- 
ies against the betas- and beta2.peptides were detected with an 
enzyme immunoassay performed in blinded manner. In ni e 
selected (seropositive) cases, the immunoglobulin G (IgG) frac- 
tion was tested for functional effects on the rate of beating of 
cultured neonatal r tcardiomyocytes. 
Results. Antibodies recognizing thebetas- and betaz-peptides 
were found in 11 (52.3%) of 21 patients with ventricular arrhyth- 
mias (p < 0.01), 5 (35.7%) of 14 patients with conduction 
disturbances (p < 0.05), 3 (13.6%) of 22 patients with atrial 
arrhythmias (p > 0.05) and 11 (37.9%) of 29 patients with dilated 
cardiomyopathy (p < 0.05) compared with 15 (14.8%) of 101 
control subjects. A rapid increase in the rate of beating of the 
cultured cardiomyocytes was induced by IgG from a selected 
group of patients, suggesting a  agonist-like interaction with a 
functional epitope. This response was mediated by stimulation of 
both the beta l- and betaz-adrenoceptors in the patients with 
primary ventricular arrhythmias but only the betal-adrenoceptors 
in the patients with idiopathic dilated cardiomyopathy. 
Conclusions. Primary ventricular arrhythmias and conduction 
disturbances, like idiopathic cardiomyopathy, show a high preva- 
lence of antibodies interacting with functional epitopes of the 
beta-adrenoceptors, suggesting a common or si ilar abnormal 
immunoregulatory process. 
(JAm CoU Cardiol 1995;26:864-9) 
The past decade has seen considerable progress in the delin- 
eation of the structure of beta-adrenoceptors. The primary 
sequences of the beta1- and beta2-adrenoceptors were derived 
from the corresponding DNA sequences (1-3), and the second 
extracellular loop was postulated to contain the T and B cell 
epitopes necessary for induction of an immune response (4). 
Two synthetic peptides corresponding to the predicted se- 
quences for the second extracellular loop of the human betas- 
and beta2-adrenoceptors were used as antigenic targets to 
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screen for receptor-specific antibodies in European patients 
with idiopathic dilated cardiomyopathy (5), a condition in 
which an autoimmune mechanism has been considered to play 
a major role (6-8). Using an enzyme immunoassay, sera from 
patients with idiopathic dilated cardiomyopathy were shown to 
monospecifically recognize the betal-peptide (5). The afffinity- 
purified antibodies had an inhibitory effect on radioligand 
binding to the betal-adrenoceptor of C6 rat glioma cells, 
recognized the receptor protein by immunoblot and bound in 
situ to human myocardial tissue. Antibodies recognizing both 
the betas- and beta2-peptides were later shown to be highly 
prevalent in patients with Chagas' heart disease (9,10), a 
specific form of dilated cardiomyopathy in which an autoim- 
mune mechanism has also been implicated (11,12). 
In view of the demonstration of anti-beta-adrenoceptor 
antibodies in these two etiologically different forms of car- 
diomyopathy, we investigated the presence of these antibodies 
in patients with cardiac arrhythmias and conduction distur- 
bances unrelated to cardiomyopathy or any other manifest 
evidence of cardiac involvement. Such onditions are well 
known to the clinical cardiologist, who often has difficulty 
defining the etiology and pathogenesis of these complications, 
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Table I. Seropositive Results in 57 Patients With Primary Electrical Abnormalities 
No. of Pts With 
Electrical Abnormali~, No. of Pts Positive Sera 
Group la (atrial Paroxysmal atrial fibrillation and/or 7 0 
arrhythmias [22 ptsll flutter 
Frequent a rial premature b ats 12 3 
[>-I,(X)0/24 h on Holler ECG) 
Sinus node dysfunction 3 0 
Frequent, uniform, nonrepetitive PVCs 6 3 
(->3(I/h on Holter ECG) 
Frequent, uniform, repetitive PVCs 4 1 
Frequent, multiform, nonrepetitive PVCs 2 0 
Frequent, multiform, repetitive PVCs 8 6 
VTNF 1 0 
lntraventricular block 10 3 
AV block? 4 2 
Group lb (ventricular 
arrhythmias 121 pts]) 
Group lc (conduction 
disturbances [14 pts]) 
*Includes five patients (Pts) with left bundle branch block, four with left anterior hemiblock (one with coexisting 
rate-dependent lef bundle branch block) and one with right bundle branch block plus left anterior hemiblock. ?Includes 
three patients with complete atrioventricular (AV) block and one with second-degree AV block. ECG = electrocardio- 
gram: PVCs =: premature ventricular contractions: VF ventricular fibrillation; VT - ventricular tachycardia. 
which include frequent atrial and ventricular arrhythmias, 
sinus node dysfunction and various forms of intraventricular 
and atrioventricular (AV) block. These conditions may be 
lumped together as "primary electrical cardiac abnormalities." 
Our major objective was to study the prevalence of anti-beta- 
adrenoceptor antibodies in patients with these electrical ab- 
normalities compared with healthy and cardiopathic ontrol 
subjects and with a new series of patients with idiopathic 
dilated cardiomyopathy. 
Methods  
One hundred eighty-seven patients, all recruited at Ramos 
Mejia Hospital in Buenos Aires, were selected and allocated to 
one of three groups. Group 1 included 57 patients with primary 
electrical abnormalities (31 men, 26 women; mean age 41.7 
years, range 15 to 73). Criteria for inclusion were the presence 
of atrial arrhythmias (group la), ventricular arrhythmias 
(group lb) or conduction disturbances (group lc) (Table 1). 
The absence of any other cardiac abnormality (or any other 
acute or chronic illness) was established in all patients on the 
basis of 1) careful history and clinical examination; 2) normal 
routine laboratory tests (including serology for Chagas' dis- 
ease); 3) absence of any electrocardiographic changes other 
than the arrhythmias and conduction disturbances; 4) normal 
findings on the echocardiogram: and 5) a normal response to 
exercise testing. Group 2 included 101 control subjects of 
whom 68 were healthy volunteers and mostly blood donors 
(group 2a [57 men, 11 women: mean age 32.9 years, range 20 
to 43]), and 33 had diverse cardiac conditions other than 
idiopathic dilated cardiomyopathy or Chagas' disease (group 
2b [25 men, 8 women; mean age 58.2 years, range 28 to 79]) 
(Table 2). Group 3 included 29 patients with idiopathic dilated 
cardiomyopathy (18 men, 11 women; mean age 45.1 years, 
range 14 to 75) and was included in the study for purposes of 
comparison between primary electrical abnormalities and id-
iopathic dilated cardiomyopathy (as for control subjects) in 
patients from the same geographic area. The diagnosis of 
idiopathic dilated cardiomyopathy was based on previously 
reported criteria (13). 
Immunoserologic test. After all clinical studies were com- 
pleted, blood samples were obtained, and the sera were diluted 
in 50% (vol/vol) glycerol and stored at -20°C until use. When 
a satisfactory number of sera were collected (30 to 90 days 
after blood extraction), the sera were processed for detection 
of antibodies directed against he synthetic betal- and beta 2- 
peptides by using previously described enzyme immunoassay 
(5). Briefly, peptides were synthesized using an automatic 
peptide synthesizer, desalted and stored at -20°C until use. 
The peptides correspond to the hypothesized second extracel- 
lular loop of the human beta-receptors. The betat-peptide 
corresponds to the sequence of amino acids 183 to 208 of the 
betat-adrenoceptors (H-W-W- R-A-E-S-D-E-A-R-R-C-Y-N- 
D-P-K-C-C-D-F-V-T-N-R) and the beta2-peptide to the se- 
quence 172 to 197 of the beta2-adrenoceptors H-W-Y-R-A- 
Table 2. Seropositive Results and Clinical Diagnosis tn 33 
Cardiopathic Control Subjects 
No. of Pts With 
Clinical Diagnosis No. of Pts Positive Sera 
Hypertrophic ardiomyopathy 15 2 
lschemic heart disease 7 0 
Valvular heart disease 5 0 
Hypertensive heart disease 2 0 
Alcoholic cardiomyopathy 1 0 
Cardiac sarcoidosis 1 0 
Kawasaki disease 1 0 
Familial periodic paralysis 1 0 
with ventricular arrhythmias 
Pts - patients. 
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T-H-Q-E-A-I-N-C-Y-A-N-E-T-C-C-D-F-F-T-N-Q). Fifty 
microliters of 0.1 mol/liter sodium carbonate solution supple- 
mented with 1% (vol/vol) beta-mercaptoethanol containing 
50/xg/ml of peptide was absorbed for 1 h at room temperature 
on microtiter plates. The wells were then saturated with 
phosphate-buffered saline solution [16 mmol/liter phosphate, 
150 retool/liter sodium chloride, pH 7.4]) supplemented with 
3% (vol/vol) skim milk, 0.1% (vol/vol) Tween-20 a d 0.01% 
(vol/vol) thimerosal (PMT). Fifty microliters of dilutions of 
sera from 1:20 to 1:1600 were allowed to react with the 
peptides overnight at 4°C. After washing the wells three times 
with phosphate-buffered saline solution, 0.05 ml of an afffinity- 
purified biotinylated rabbit anti-human immunoglobulin G 
(IgG) antibody solution diluted 1:1,000 in PMT was allowed to 
react for 1 h at room temperature. After three additional 
washings, the bound biotinylated antibody was detected by 
incubation of the plates for 1 h at room temperature with 0.05 
ml/well of a 1-~g/ml solution of streptavidin-peroxidase in 
PMT followed by three washings in phosphate-buffered saline 
solution and addition of the chromogenic substrate hydrogen 
peroxide (2.5 mmol/liter) 2,2'-azino-di-(ethylbenzthiazoline) 
sulfonic acid (2 mmol/liter). Thereafter, 30-rain optical densi- 
ties were read at 405 nm in a Micro Elisa Reader (Molecular 
Devices). 
All determinations were performed in the same laboratory 
(WaUenberg Laboratory, Sahlgren's Hospital, G6teborg, Swe- 
den) in four separate batches (during a period of 18 months) 
under blinded conditions except for the healthy control sub- 
jects. Each batch of sera included 10% to 50% from the 
healthy control subjects. Sera were considered positive when- 
ever optical density values exceeded the mean value + 2 SD of 
optical densities obtained for the healthy control subjects, and 
after exclusion of those whose optical density values exceeded 
this limit, which were considered as positive healthy control 
sera .  
Functional test. In nine selected patients (four with pri- 
mary electrical abnormalities, four with idiopathic dilated 
cardiomyopathy, one healthy control subject) whose sera 
were shown to be positive, the IgG fraction was isolated by 
ammonium sulfate precipitation a d tested for functional 
(chronotropic) effects on the rate of beating of cultured 
neonatal rat cardiomyocytes, as previously described (14). 
Briefly, single cells were dissociated from the minced ventricles 
with a 0.2% solution of trypsin and were cultured at 37°C for 
4 days as monolayers (90,000 cells/cm2). On the day of the 
experiment, he medium was replaced, and the cells were 
incubated for 2 h as monolayers on a slowly moving rocker 
apparatus. During this stage, cells were sensitized for beta:- 
adrenoceptor response by addition of 10 mmol/liter of 15- 
hydroxyeicositetraenic acid (15). The flasks were then trans- 
ferred to the heated stage of an inverted Zeiss microscope on 
which 10 small circular fields of the cell layer were inspected a  
37°C through the perforations of a metal template. The 
number of beats of a selected isolated myocardial cell or a 
cluster of synchronous contracting cells in each of the 10 fields 
was visually counted for 15 s each time. This procedure was 
repeated twice in different cultures to yield results representing 
a total of 10 cells or cell clusters, before and 60 min after 
preincubation with the IgG at dilutions of 1:10 to 1:100. The 
counting was repeated after the subsequent and successive 
addition (without washing) of first the selective betal- 
adrenergic blocking agent bisoprolol (1 txmol/liter), and then 
the selective beta2-blocker ICI 118,551 (30 nmol/liter). All 
functional tests were performed in a blinded manner. 
Statistical analysis. Analysis of variance (a Statview SE+ 
Graphics TM version 1.03 software package on a Macintosh 
personal computer) was used to define the statistical signifi- 
cance of differences in the prevalence of anti-beta I and 
anti-beta2-adrenoceptor antibodies in the different groups of 
patients. Significance was assessed at p < 0.05. The increase in 
beating frequency of cultured rat cardiomyocytes compared 
with the corresponding control period before addition of IgG 
was analyzed using a paired Student t test. Results are ex- 
pressed as mean value + SEM. A probability level of p < 0.05 
was chosen as the least significant difference. 
Resu l ts  
The prevalence of antibodies directed against the beta- 
adrenoceptors differed in the three groups of patients with 
primary electrical cardiac abnormalities. Thus, antibodies rec- 
ognizing the beta 1- or beta2-peptides, or both, were found in 11 
(52.3%) of 21 (p < 0.01) patients with ventricular rrhythmias, 
in 5 (35.7%) of 14 (p < 0.05) patients with conduction 
disturbances and in 3 (13.6%) of 22 (p > 0.05) patients with 
atrial arrhythmias compared with 15 (14.8%) of 101 control 
patients. In patients with idiopathic dilated cardiomyopathy, 
the prevalence was 11 (37.9%) of 29 (p < 0.05). Other dif- 
ferences became apparent when the prevalence of anti-betal- 
and anti-beta2-adrenoceptor antibodies was analyzed indepen- 
dently and against the healthy and cardiopathic control subjects 
(Figure 1). No statistical differences were found in the prevalence 
of either anti-beta 1- or anti-beta2-adrenoccptor antibodies be- 
tween healthy and cardiopathic control subjects. Antibodies rec- 
ognizing the betal-peptide with a difference that was significant 
against both e healthy and cardiopathic control subjects oc- 
curred in patients with primary ventricular arrhythmias as well as 
in those with idiopathic dilated cardiomyopathy (Fig. 1). In 
contrast, antibodies recognizing the betaz-peptide occurred only 
in patients with primary ventricular arrhythmias, with a difference 
that was significant versus the cardiopathic but not he healthy 
control subjects. Although it failed to reach statistical significance, 
a positive trend toward recognition of the betal-peptide occurred 
in the patients with conduction disturbances. In contrast o all 
other groups, the sera of patients with atrial arrhythmias failed to 
show any recognition of the presence of either anti-beta 1- or 
anti-beta2-adrenoceptor antibodies. 
Because ventricular arrhythmias andconduction distur- 
bances occur commonly in patients with idiopathic dilated 
cardiomyopathy (13), we compared the prevalence of the 
antibodies in patients with (23 of our 29 patients) and without 
these abnormalities (the remaining 6 patients). As shown in 
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Figure 1. Percent of sera recognizing the anti-beta c (left) and 
anti-beta2-peptides (right) in patients with primau atrial arrhythmias 
(AA), conduction disturbances (CD), ventricular arrhythmias (VA)
and idiopathic dilated cardiomyopathy (IDC) compared with healthy 
(HC) and cardiopathic control subjects (CC). *p < 0.05 versus healthy 
control subjects. **p < 0.05 versus eardiopathie control subjects. See 
text for further discussion. 
Figure 2, the high prevalence of anti-beta-adrenoceptor anti- 
bodies occurred only in patients with ventricular arrhythmias 
and conduction disturbances. 
Functional effects of anti-beta-adrenoceptor antibodies. 
The basal beating rate of cultured rat cardiomyoc~es was 
140 _+ 20 beats/min. As shown in Figure 3, the IgG from two 
patients with primary ventricular arrhythmias whose sera rec- 
ognized both the beta]- and beta2-peptides, caused a positive 
chronotropic effect hat was partially neutralized by the selec- 
tive betarblocker bisoprolol and completely abolished by the 
selective beta2-blocker ICI 118,551. It is clear that the chrono- 
tropic effect was mediated by stimulation of both the betal- 
and beta2-adrenoceptors. In contrast, the lgG from two 
patients with idiopathic dilated cardiomyopathy whose sera 
recognized only the betal-peptide induced a chronotropic 
response that was completely abolished by bisoprolol, suggest- 
Figure 2. Percent of sera recognizing the beta~-peptide (POSITIVE 
SERA) in 29 patients with idiopathic dilated cardiomyopathy, according 
to the presence or absence of ventricular arrhythmias (VA) and 
conduction disturbances (CD). One patient had both ventricular 
arrhythmias and conduction disturbances. 
POSITIVE SERA (%) 
50[ 42.8 
4(::1 
30 
20 
10 
0 
VA 
40 
CD 
. . . . . . . . . . . . . . . .  16.6 . . . . . . . .  
NO VA-CD 
ing that the effect was entirely mediated by stimulation of the 
betal-adrenoceptors. An identical response occurred in two 
other patients with idiopathic dilated cardiomyopathy (not 
shown) and had previously been reported (17) to result from 
the use of affinity-purified anti-betal-adrenoceptor antibodies. 
In the single patient with primary intraventricular block, whose 
serum only recognized the beta~-peptide, the responses to IgG 
and bisoprolol were similar to that in patients with idiopathic 
dilated cardiomyopathy. In one of the three patients with 
primary ventricular arrhythmias and in one healthy control 
subject whose sera recognized only the betaa-peptide, IgG 
failed to cause any significant chronotropic effect. A similar 
lack of functional response was documented in four other 
serologically positive healthy control subjects tested in our 
previous studies (17), suggesting the existence of "naturally 
occurring antibodies" that may recognize the synthetic pep- 
tides but not the specific functional epitopes. 
Discuss ion  
Our study confirms the finding that patients with idiopathic 
dilated cardiomyopathy exhibit a high prevalence of anti-beta- 
adrenoceptor antibodies and demonstrates that a similarly 
high or even higher prevalence of such antibodies also occurs 
in patients with primary ventricular arrhythmias or conduction 
disturbances, orboth. We also showed that IgG from the same 
patients results in a similar positive chronotropic response (in 
in vitro experiments), mediated by stimulation of the betar 
adrenoceptors in patients with dilated cardiomyopathy and by 
stimulation of both the beta1- and beta2-adrenoceptors in 
patients with primary ventricular arrhythmias. In view of these 
similarities, we were initially inclined to believe that primary 
ventricular arrhythmias or conduction disturbances, or both, 
may represent early or parallel manifestations of idiopathic 
dilated cardiomyopathy preceding the advanced stage of car- 
diac failure or abortive forms of the same disease. However, 
some unexpected findings raised doubts regarding the full 
validity of this hypothesis. Thus, the high prevalence of the 
antibodies in our patients with idiopathic dilated cardiomyop- 
athy occurred only in those patients with ventricular arrhyth- 
mias or conduction disturbances (Fig. 2). Similarly, when a 
ligand-binding inhibition assay was used to screen for anti- 
beta-adrenoceptor antibodies in patients with idiopathic di- 
lated cardiomyopathy (18), 6 (30%) of 20 were seropositive 
when the dilated cardiomyopathy was associated with complex 
ventricular arrhythmias, whereas only 1 (5%) of 20 was sero- 
positive when the arrhythmias were absent. These observations 
seem to suggest hat anti-beta-adrenoceptor antibodies corre- 
late better or more directly with ventricular arrhythmias and 
conduction disturbances than with dilated cardiomyopathy 
itself. 
Potential arrhythmogenicity and cardiotoxicity of antibod- 
ies. It has been shown (14,17) that a low concentration (0.02 
to 0.41 nmol/liter) of affinity-purified anti-beta]-adrenoceptor 
antibodies from patients with idiopathic dilated cardiomiopa- 
thy or immunized rabbits may cause a strong chronotropic 
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stimulation (up to 80% of the maximal effect of isoproterenol) 
in cultured rat cardiomyocytes. Unlike th effect of isoproter- 
enol, the effect of the antibodies persists unchanged for many 
hours (17). This lack of short-term desensitization may be 
expected to sustain and reinforce the agonist-like effects of the 
antibodies. If similar effects occurred in vivo, the antibodies 
might exert arrhythmogenic as well as cardiotoxic effects like 
those shown to be caused by catecholamines, although this has 
yet to be proved in appropriate experimental models. 
Reappraisal of primary ventricular arrhythmias and con- 
duction disturbances. In view of their association with anti- 
beta-adrenoceptor antibodies, the significance of these abnor- 
malities needs to be reevaluated. In several of our patients with 
advanced idiopathic dilated cardiomyopathy, left bundle 
branch block or ventricular arrhythmias, or both, had been 
documented 10 to 20 years earlier, at a time when cardiac size 
was still normal, suggesting that the electrical abnormalities 
were indeed the earliest manifestations of the immunopatho- 
logic process conducive to the development of overt dilated 
cardiomyopathy. However, in some patients with primau' 
ventricular arrhythmias or intraventricular block associated 
with the antibodies, a retrospective follow-up of up to 20 years 
failed to reveal any deterioration. Prospective follow-up stud- 
ies will be needed to determine whether such abnormalities in 
the presence of anti-beta-adrenoceptor antibodies may serve 
as diagnostic or prognostic markers for idiopathic dilated 
cardiomyopathy. 
Study limitations. Anti-beta-adrenoceptor antibodies it~ 
normal subjects. The main difficulty in the present study was 
the relatively high prevalence of antibodies recognizing the 
betas- and beta2-peptides in the control subjects. It is also true 
that the specificity and sensitivity of the enzyme immunoassay 
utilized in our study have not yet been strictly defined. 
However, these limitations do not detract from the practical 
usefulness of this procedure for the screening of anti-beta- 
adrenoceptors antibodies. Thus, this simple assay has served to 
single out idiopathic dilated cardiomyopathy, primary ventric- 
ular arrhythmias nd Chagas' heart disease as the only cardiac 
conditions associated with a high prevalence of these antibod- 
ies (9). The validity of our results is also supported by the 
following findings: 
1. The prevalence of the antibodies in our patients with 
dilated cardiomyopathy was similar to that previously demon- 
strated with the same method (5) or with a ligand-binding 
inhibition assay (16,18). 
2. The results were also essentially similar in each of the 
four batches of sera from all our patients, in regard to both the 
test and control cases. 
3. Correct identification of both the anti-beta 1-and anti- 
beta2-adrenoceptor antibodies was demonstrated (Figure 3) in 
the seropositive tests counterchecked with a functional test. 
However, the functional test is too complex and labor intensive 
to be useful in a large number of patients, as in our study. 
4. Conversely, the seropositive r sults in the control sub- 
jects seem to imply the existence of natural antibodies deprived 
of any functional effect. In fact, these "false" seropositive 
results tend to become negative when enzyme immunoassay is 
performed utilizing lgG instead of the full serum (unpublished 
observations). 
Conclusions and clinical implications. Primary ventricular 
arrhythmias and conduction disturbances, like idiopathic di- 
lated cardiomyopathy, are associated with a high prevalence of
antibodies interacting with functional epitopes mapped to the 
second extracellular loop of the beta-adrenoceptors. There- 
fore, these cardiac abnormalities seem to be interrelated 
through a similar abnormal immunoregulatory p ocess involv- 
ing the beta-adrenoceptors. Theantibodies exert agonist- or 
catecholamine-like effects that might facilitate the occurrence 
of ventricular arrhythmias nd play a role in the development 
of dilated cardiomyopathy. These observations open new in- 
sights into the pathogenesis, diagnosis, prognosis and treat- 
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Figure 3. Positive chronotropic effect 
(increase in beats/minute) on cultured 
neonatal rat cardiomyocytes (l ft panel) 
induced by immunoglobulin G obtained 
from a selected group of seropositive 
patients. Sera from a single healthy con- 
trol subject, wo patients with diopathic 
dilated cardiomyopathy (IDC1 and 
IDC2), the third patient with primary 
ventricular arrhythmias (V rrh3) and 
the single patient with intraventricular 
block (Block 1) recognized the beta l- 
peptide only. Two of the three sera from 
patients with primary ventricular ar- 
rhythmias (Varrhl and Varrh2) recog- 
nized both the beta 1- and beta 2- 
peptides. The middle and right panels 
show the effect of adding, successively 
and without washing, a selective beta l- 
blocker (bisoprolol) and a selective be- 
ta2-blocker (ICI 118,551). See text for 
further discussion. 
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ment of such conditions and may be the starting point for many 
new studies. 
We are indebted to Brian Hoffman. MD for valuable comments and criticisms, 
Estela Feigelson, MD and Horacio Selva, MD for assistance in the preparation 
of the manuscript and Cecilia McKeon for secretarial skill. 
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